Meta Platforms earnings missed by $5.63, revenue topped estimates
Director Todd Bazemore of KALA BIO, Inc. (NASDAQ: KALA), a company currently valued at $5.62 million, sold 47,768 shares of common stock on October 22, 2025, according to a Form 4 filing with the Securities and Exchange Commission. This insider transaction comes as the stock trades near its 52-week low, having declined over 80% in the past year. The shares were sold at a weighted average price of $0.83, for a total transaction value of $39,647.
The prices for the sales ranged from $0.82 to $0.85. Following the transaction, Bazemore directly owns 35,932 shares of KALA BIO, Inc., which includes 35,732 unvested RSUs. The filing also indicates that Bazemore indirectly owns 1 share of common stock through his son.
In other recent news, Kala Bio, Inc. announced it received a default notice from Oxford Finance LLC concerning its Loan and Security Agreement, with a $29.1 million loan declared immediately due. This development follows the company’s announcement that its KPI-012 treatment failed to meet the primary endpoint in a Phase 2b clinical trial for persistent corneal epithelial defect (PCED). The trial results showed no significant difference between the KPI-012 treatment arms and the placebo, leading the company to cease development of the treatment and its mesenchymal stem cell secretome platform. Analysts from Mizuho have noted the absence of detailed data from the trial and expect weakness in Kala Bio’s stock following these results. Additionally, Kala Bio has scheduled its 2025 annual shareholder meeting for December 11, with further details to be provided in a forthcoming proxy statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.